InnoCare Pharma Ltd. Class A 688428

Key Stats for LLY StockPast week’s performance: 1. 6%52-week range: $716 to $1,293Valuation model target price: $1,834Implied upside: 54.

Eli Lilly (NYSE:LLY) received FDA approval for Olumiant to treat pediatric patients with severe alopecia areata. The FDA also cleared once weekly insulin Onswik for adults with type 2 diabetes, adding a new dosing option. Eli Lilly agreed a global drug discovery alliance with InnoCare Pharma valued at up to US$3.35b in research and licensing commitments. These combined FDA approvals and the US$3.35b InnoCare alliance deserve weighing against the rest of our Eli Lilly analysis. We have also...

Big pharma is still paying up, but more often for delivery and discovery engines than for a single late-stage asset.

Lilly will pay $100 million upfront to work with the Beijing-based biotech on as many as five undisclosed drug targets

InnoCare, which already has three approved therapies, describes itself as a biopharma focusing on cancer and autoimmune disease treatments.

Lilly wagered up to $3.35 billion in its fourth China-focused alliance since January 2025. Elsewhere, analysts are now more confident about one of Vertex’s top prospects and an RNA drug succeeded against a rare form of ALS.

BEIJING, Sept. 24, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Company has entered into a strategic research collaboration and license agreement with Eli Lilly and Company (“Lilly”) to develop new medicines. InnoCare will leverage its proprietary drug discovery platform and extensive research experience to discover and advance compounds against up to

BEIJING, Sept. 08, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has approved its Investigational New Drug (IND) application to initiate clinical trials for ICP-B381, the novel bispecific ADC targeting PSMA and STEAP1, for the treatment of solid tumors including p

BEIJING, Aug. 24, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the interim results and business highlights for the six months ended 30 June 2026. InnoCare delivered robust revenue growth and strengthened profitability in the first half of 2026, driven by strong commercial execution and global business development collaborations. In the first half of 2026, the Company’s revenue

BEIJING, Aug. 18, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has approved the registrational Phase III study of the Company's novel BCL2 inhibitor mesutoclax (ICP-248) in combination with azacitidine versus venetoclax with azacitidine in elderly or unfit pat

BEIJING, Aug. 03, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that orelabrutinib, in combination with mesutoclax (ICP-248), has been granted Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) for the treatment of patients with marginal zone lymphoma (MZL) who have received

BEIJING, July 27, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that its novel TYK2 (Tyrosine Kinase 2) inhibitor fadeucravacitinib (ICP-488) met the primary endpoint in the registrational Phase III clinical study in patients with moderate-to-severe plaque psoriasis. The Phase III study is a randomized, double-blind, placebo-controlled, multicenter registrationa

The new lawsuits add to a web of legal disputes over technology involved in COVID vaccines. Elsewhere, a prolific AI biotech inked another deal and Insmed strengthened support for a closely watched blood pressure drug.

BEIJING, July 16, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Phase II portion of the Phase II/III trial of its TYK2 inhibitor Soficitinib (ICP-332) for non-segmental vitiligo has met the primary endpoint. The study is a Phase II/III randomized, double-blind, placebo-controlled, parallel-group, adaptive, multicenter clinical trial. The study consists

BEIJING, July 15, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that registrational phase III clinical study results of novel TYK2 (Tyrosine Kinase 2) inhibitor soficitinib (ICP-332) met the primary endpoint in patients with moderate-to-severe atopic dermatitis (AD). The Phase III study is a randomized, double-blind, placebo-controlled, multicenter registrationa

BEIJING, July 14, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428) today announced that Signal Transduction and Targeted Therapy (STTT), a Nature Portfolio journal, published a paper titled "Orelabrutinib versus chemoimmunotherapy in treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma: a randomized, phase 3 trial." The paper concludes that orelabrutinib significantly prolongs progression-free survival (PFS) and reduces the risk of disease progression or dea

BEIJING, July 10, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), today announced that the Journal of Autoimmunity has published results from a clinical study evaluating orelabrutinib, a BTK (Bruton’s tyrosine kinase) inhibitor, in patients with systemic lupus erythematosus (SLE). The study confirmed for the first time that orelabrutinib is well-tolerated and efficacious in patients with SLE, marking orelabrutinib as the first BTK inhibitor to show clinical efficacy in treat

BEIJING, July 05, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has been dosed in the clinical trial of novel CDH17 targeted ADC, ICP-B208, in China. Developed from InnoCare’s in-house ADC platform, ICP-B208 is a novel ADC comprising a humanized anti-CDH17 monoclonal antibody conjugated to a potent, in-house invented payload via a protease

BEIJING, June 15, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that over 40 clinical studies of the Company's novel BTK inhibitor orelabrutinib were presented at the European Hematology Association (EHA) 2026 Congress. Clinical data on the efficacy and safety of orelabrutinib in treatment-naïve (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/S

InnoCare Pharma (SEHK:9969) has attracted fresh attention after reporting Phase IIb success for its BTK inhibitor orelabrutinib in systemic lupus erythematosus and releasing updated efficacy and safety data for BCL2 inhibitor mesutoclax. See our latest analysis for InnoCare Pharma. Despite the clinical updates and governance changes over recent weeks, InnoCare Pharma’s share price return has moved the other way, with the stock down 21.71% over 30 days and 17.20% year to date, while the 3 year...